• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab.

作者信息

Heine A, Kristiansen G, Schild H H, Brossart P

机构信息

Medical Clinic III for Oncology, Hematology and Rheumatology.

Insitute for Pathology.

出版信息

Ann Oncol. 2016 Sep;27(9):1813-4. doi: 10.1093/annonc/mdw243. Epub 2016 Jun 20.

DOI:10.1093/annonc/mdw243
PMID:27329248
Abstract
摘要

相似文献

1
Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab.使用PD-1抑制剂纳武单抗成功治疗难治性平滑肌肉瘤。
Ann Oncol. 2016 Sep;27(9):1813-4. doi: 10.1093/annonc/mdw243. Epub 2016 Jun 20.
2
Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors.免疫检查点抑制在铂难治性生殖细胞肿瘤中的活性。
Ann Oncol. 2016 Jul;27(7):1356-60. doi: 10.1093/annonc/mdw146. Epub 2016 Mar 30.
3
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.建立抗程序性死亡蛋白1（PD-1）免疫检查点抑制剂治疗的辅助诊断方法。
Ann Oncol. 2016 Oct;27(10):1966-9. doi: 10.1093/annonc/mdw288. Epub 2016 Aug 8.
4
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.抗 PD-1 抗体纳武利尤单抗治疗铂耐药卵巢癌患者的安全性和抗肿瘤活性。
J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8.
5
Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?纳武利尤单抗诱导的炎性多关节炎后使用阿替利珠单抗：抗PD-1相关免疫毒性后能否给予抗PD-L1免疫治疗？
J Thorac Oncol. 2018 Jun;13(6):e102-e103. doi: 10.1016/j.jtho.2018.01.027.
6
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.美国食品药品监督管理局批准摘要：纳武单抗用于治疗在铂类化疗期间或之后病情进展的转移性非小细胞肺癌。
Oncologist. 2016 May;21(5):634-42. doi: 10.1634/theoncologist.2015-0507. Epub 2016 Mar 16.
7
Nivolumab: targeting PD-1 to bolster antitumor immunity.纳武单抗：靶向程序性死亡受体1以增强抗肿瘤免疫力。
Future Oncol. 2015;11(9):1307-26. doi: 10.2217/fon.15.52. Epub 2015 Mar 23.
8
Nivolumab: a review in advanced squamous non-small cell lung cancer.纳武利尤单抗：晚期鳞状非小细胞肺癌的研究进展。
Drugs. 2015 Nov;75(16):1925-34. doi: 10.1007/s40265-015-0492-9.
9
Targeting Programmed Cell Death 1 in Ovarian Cancer.靶向卵巢癌中的程序性细胞死亡蛋白1
J Clin Oncol. 2015 Dec 1;33(34):3987-9. doi: 10.1200/JCO.2015.63.7785. Epub 2015 Oct 26.
10
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.纳武单抗单药免疫治疗晚期子宫平滑肌肉瘤：一项2期研究的结果
Cancer. 2017 Sep 1;123(17):3285-3290. doi: 10.1002/cncr.30738. Epub 2017 Apr 25.

引用本文的文献

1
The concomitant of non-classical stereotactic body radiotherapy with tislelizumab based on multidisciplinary modalities for leiomyosarcoma: A case report.非经典立体定向体放射治疗联合替雷利珠单抗多学科综合治疗平滑肌肉瘤的伴随病例报告。
Medicine (Baltimore). 2024 Nov 8;103(45):e40278. doi: 10.1097/MD.0000000000040278.
2
Targeting the Molecular and Immunologic Features of Leiomyosarcoma.针对平滑肌肉瘤的分子和免疫特征
Cancers (Basel). 2023 Mar 31;15(7):2099. doi: 10.3390/cancers15072099.
3
Efficacy of PD-1 inhibitors combined with pegylated liposomal doxorubicin and dacarbazine compared with liposomal doxorubicin and dacarbazine in advanced leiomyosarcoma patients: a retrospective, single-institutional cohort study.
与脂质体阿霉素和达卡巴嗪相比，PD-1抑制剂联合聚乙二醇化脂质体阿霉素和达卡巴嗪治疗晚期平滑肌肉瘤患者的疗效：一项回顾性、单机构队列研究。
Ann Transl Med. 2022 Sep;10(18):1000. doi: 10.21037/atm-22-3963.
4
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.肿瘤免疫治疗的治疗靶点和生物标志物：反应与无反应。
Signal Transduct Target Ther. 2022 Sep 19;7(1):331. doi: 10.1038/s41392-022-01136-2.
5
Indian experience with immunotherapy in sarcoma and gastrointestinal stromal tumors: a retrospective study.印度在肉瘤和胃肠道间质瘤免疫治疗方面的经验：一项回顾性研究。
Future Sci OA. 2022 Apr 20;8(5):FSO795. doi: 10.2144/fsoa-2021-0117. eCollection 2022 Mar.
6
Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study.安罗替尼治疗晚期平滑肌肉瘤的疗效与安全性回顾性分析：一项真实世界研究
Cancer Manag Res. 2022 May 11;14:1703-1711. doi: 10.2147/CMAR.S357334. eCollection 2022.
7
Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN.病例报告：携带PTEN双等位基因缺失的不可切除错配修复缺陷型平滑肌肉瘤对抗血管生成和免疫检查点阻断的完全缓解
Front Oncol. 2022 Feb 14;12:802074. doi: 10.3389/fonc.2022.802074. eCollection 2022.
8
Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol.Ⅱ期研究：阿替利珠单抗联合放疗治疗寡转移软组织肉瘤：STEREOSARC 试验方案。
BMJ Open. 2020 Sep 23;10(9):e038391. doi: 10.1136/bmjopen-2020-038391.
9
Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.PD-L1 和 IDO1 表达与软组织平滑肌肉瘤中 JAK-STAT 通路激活的相关性。
J Cancer Res Clin Oncol. 2021 May;147(5):1451-1463. doi: 10.1007/s00432-020-03390-9. Epub 2020 Sep 20.
10
Tumor regression after combination of radiation and PD-1 antibody nivolumab treatment in a patient with metastatic mediastinal leiomyosarcoma: a case report.患者转移性纵隔平滑肌肉瘤经放射联合 PD-1 抗体纳武利尤单抗治疗后肿瘤消退：病例报告。
Cancer Biol Ther. 2019;20(4):408-412. doi: 10.1080/15384047.2018.1537577. Epub 2018 Nov 2.